Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disease that mediated by BCR / ABL oncogenic signaling. CML can be targeted with the imatinib, dasatinib, and nilotinib TKI inhibitors, the latter two of them have been approved for imatinib-resistant or -intolerant CML patients. The TKIs resist...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2022-09, Vol.39 (9), p.126-126, Article 126
Hauptverfasser:	Ozel, Buket, Kipcak, Sezgi, Biray Avci, Cigir, Sabour Takanlou, Maryam, Sabour Takanlou, Leila, Tezcanli Kaymaz, Burcin, Karatekin, Ilknur, Gunduz, Cumhur, Selvi Gunel, Nur
Format:	Artikel
Sprache:	eng
Schlagworte:	Binding sites Breast cancer Cytotoxicity Hematology Internal Medicine Kinases Leukemia Medicine Medicine & Public Health Mutation Oncology Original Paper Pathology Protein folding
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!